- Intelligent Bio Solutions (NASDAQ: INBS) integrates Latin American Spanish into the Intelligent Fingerprinting Drug Screening System.
- The Latin American drug screening market is expected to reach USD 1.1 billion by 2030.
- Company prepares for U.S. market entry with FDA 510(k) submission.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) has announced the successful integration of Latin American Spanish into its Intelligent Fingerprinting Drug Screening System. This significant enhancement in multilingual capabilities also includes English and Arabic, allowing broader access across Spanish-speaking regions.
The strategic expansion comes as the Latin American drug screening market is projected to grow to USD 1.1 billion by 2030, fueled by public safety initiatives and increased demand for compliance programs in workplaces. This update positions INBS favorably to address the needs of Spanish-speaking markets, enhancing accessibility in North America, Central America, South America, and Europe.
The enhancement is part of a larger multilingual upgrade aiming to expand the system's usability to over 4 billion potential users worldwide. Currently, INBS serves over 400 accounts across 19 countries and is setting the stage for entry into the U.S. market following its FDA 510(k) submission completed in December 2024.
This language integration is a key component of INBS's broader growth strategy, including an anticipated penetration into new markets and regions, supported by its innovative, rapid, non-invasive testing solutions.
